Introduction
============

Adult stem cell migration through human hematopoietic tissue requires the chemokine CXCL12 and its receptor CXCR4. In addition, human leukocyte elastase (HLE) plays a key role. When HLE is located on the cell surface (HLECS), it acts not as a proteinase, but as a receptor for α1proteinase inhibitor (α~1~PI, α1antitrypsin). Binding of α~1~PI to HLECS forms a motogenic complex. We previously demonstrated that α~1~PI deficiency attends HIV-1 disease. Here we investigate the mechanism and therapeutically address the α~1~PI deficiency of HIV-1 infection.

Materials and methods
=====================

Blood was collected from 30 HIV-1 uninfected and 39 HIV-1 infected adults. Residual sera was obtained from 20 HIV-1 uninfected chimpanzees, 2 chimpanzees pre- and 42 months post-HIV-1 challenge, 12 HIV-1-immunized macaques, and 3 SHIV-infected macaques. Three HIV-1 infected individuals received α~1~PI augmentation therapy.

Results
=======

In HIV-1 uninfected individuals, CD4^+^ lymphocytes were correlated with the combined factors α~1~PI, HLECS+ lymphocytes, and CXCR4+ lymphocytes (r^2^ = 0.91, p \< 0.001, n = 30), but not CXCL12. In contrast, in HIV-1 individuals with \>220 CD4 cells/µl, CD4+ lymphocytes were correlated solely with active α1PI (r^2^ = 0.93, p \< 0.0001, n = 26). The monoclonal anti-HIV-1 antibody 3F5 present in HIV-1 patient blood bound and inactivated human α~1~PI. Chimpanzee α~1~PI differs from human α~1~PI by a single amino acid which lies within the 3F5-binding epitope. Unlike human α~1~PI, neither chimpanzee nor macaque α~1~PI bound to 3F5, nor was α~1~PI depleted following HIV-1 challenge, consistent with the normal CD4^+^ lymphocyte numbers of HIV-1 infected chimpanzees. The presence of IgG- α~1~PI immune complexes correlated with decreased CD4^+^ lymphocytes in HIV-1 individuals, and α1PI augmentation quadrupled the number of immunocompetent CD4^+^ lymphocytes with no untoward effects.

Conclusions
===========

An autoimmune component of HIV-1 disease was identified and was overcome therapeutically. Results identify an achievable vaccine modification with the novel objective to protect against AIDS as opposed to the current objective to protect against HIV-1 infection.
